LOS ANGELES, Jan. 10, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. (“Revance” or “the Company”) RVNC for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before March 4, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Revance was in material breach of its distribution agreement with Teoxane SA. The Company’s breach placed it at a heightened risk of litigation as well as reputational harm. The Company’s failures also put the tender offer from Crown Laboratories, Inc. at risk of delay or amendment. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Revance, investors suffered damaged.
See also <!DOCTYPE html><html><head> <title>Investors Eye Two Top-Ranked Growth Opportunities in July</title></head><body> <h2>Favorable Market Conditions</h2> <p>As speculation mounts around future rate cuts by the Federal Reserve to stimulate the cooling U.S. economy, investors are keeping a close eye on the promising corporate earnings projections for the second quarter and beyond. Despite concerns of overheating, the bullish sentiment continues to prevail on Wall Street.</p> <h2>Hims & Hers Health, Inc.: Riding the Wave of Success</h2> <p>Hims & Hers Health, Inc. has carved a niche for itself as a leading online health company, rapidly expanding its offerings beyond male-focused treatments to a comprehensive range of health and wellness solutions for both genders. The firm, which went public in 2021 via a SPAC, has amassed close to 2 million subscribers and is setting its sights on the lucrative weight loss drugs segment.</p> <h3>Positive Growth Trajectory</h3> <p>With innovative solutions such as compounded GLP-1 injections and strategic partnerships with major retailers like Target, Hims & Hers continues to witness significant growth. The company's strong performance in Q1, marked by a 41% increase in subscribers and a 46% rise in sales, underscores its upward trajectory.</p> <h3>Financial Projections and Stock Performance</h3> <p>Zacks estimates indicate a robust revenue surge for Hims & Hers, projecting a 44% growth in FY24 and a further 31% increase in the following year. The company's stock has seen a remarkable 533% boost in its FY25 EPS estimate, earning it a coveted Zacks Rank #1 (Strong Buy). Despite a recent pullback from its peak, the stock remains a compelling investment proposition.</p> <h2>Ero Copper Corp.: Harnessing the Power of Copper</h2> <p>Ero Copper Corp., a prominent copper producer based in Vancouver, has positioned itself at the forefront of the global energy transition. With copper demand expected to surge driven by renewable energy growth and infrastructure projects, Ero Copper is poised for substantial expansion.</p> <h3>Strategic Growth Initiatives</h3> <p>The company's ambitious target to double copper production by 2025, supported by its Tucumã Project nearing completion, reflects its commitment to capitalizing on the growing market demand. Ero Copper's steady revenue growth projections point towards a promising future in the copper sector.</p> <h3>Market Position and Outlook</h3> <p>Amidst fluctuations in copper prices, Ero Copper remains resilient, with a plan in place to significantly boost revenues in the coming years. Investors eyeing the long-term potential of the copper market may find Ero Copper an attractive investment option.</p></body></html><html><head> <title>Ero Copper Corp: A Gleaming Investment Opportunity in the Growing Copper Industry</title></head><body> Ero Copper Corp: A Gleaming Investment Opportunity in the Growing Copper Industry
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rvnc-investors-have-opportunity-to-lead-revance-therapeutics-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302347715.html
SOURCE The Schall Law Firm
